Oxigene plans on presenting more data from the phase II/III study of zybrestat in thyroid cancer next month and additional phase II lung cancer data in November.
Oxigene shares closed Friday at 27 cents.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein.
>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.>To submit a news tip, send an email to: email@example.com.